TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06092684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-KTM-I
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketanest®S
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Study: NCT04686773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box
Study: NCT05246852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle education
Description: A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
Study: NCT05689164

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: fordadistrogene movaparvovec
Description: gene therapy administered in a previous study.
Study: NCT05460195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab combined with anlotinib
Description: Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab monotherapy
Description: Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
Study: NCT04523363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Maximum dosage of 500 mg tablets 2 times a day (with each meal)
Study: NCT05137028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise
Description: Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking
Study: NCT04762706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRUTCH Pathway
Description: Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
Study: NCT04909866

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE+Lenvatininb+Camrelizumab
Description: Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
Study: NCT05598762

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
Study: NCT05495724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Tislelizumab
Description: Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin
Study: NCT06060912

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Atrial Appendage Occlusion
Description: Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion
Description: Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
Study: NCT06459427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Stereotactic Brainstem Hematoma Puncture
Description: Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative non-surgical treatment
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative non-surgical treatment
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
Study: NCT06316401

Intervention type: PROCEDURE
Intervention: ESD of large LSTs under SA
Description: endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
Study: NCT05603975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 0.1mg/kg intravenous injection
Description: The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change.
Study: NCT04704791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PA-LAA shunt
Description: At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
Study: NCT06349382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate-rich beverage
Description: Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
Study: NCT04846322

Intervention type: DIAGNOSTIC_TEST
Intervention: PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)
Description: 1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan.
Study: NCT06303102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise
Description: 20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Manual PT/Conventional PT Treatment
Description: 20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
Study: NCT05765864

Intervention type: DIAGNOSTIC_TEST
Intervention: Personality Assessment Inventory-Adolescent (PAI-A)
Description: An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx

Intervention type: DIAGNOSTIC_TEST
Intervention: Inventory Of Statements About Self-Injury; ISAS
Description: A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inventory Of Statements About Self-Injury; ISAS
Description: A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669.
Study: NCT05291299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Description: Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Control/Standard of Care
Description: Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
Study: NCT05662176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Supportive Care based on trauma informed care
Description: Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.

Intervention type: OTHER
Group type: OTHER
Intervention: Standart care
Description: Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
Study: NCT06020118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
Description: Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
Description: Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Description: mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
Study: NCT05005052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vessel
Description: Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and no compression or venopharmaceutical regimen
Study: NCT05920837

Intervention type: DEVICE
Intervention: MyotonPRO
Description: Muscles' viscoelastic properties assess with myotonPRO.

Intervention type: OTHER
Intervention: Box and Block Test
Description: Upper extremity's functionality assess with Box and Block Test.
Study: NCT05173181

Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible intramedullary nail
Description: Fixation of distal ulna fracture with flexible intramedullary nail
Study: NCT05366452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPELLA CP
Description: Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT \>250 s. As soon as the device is in place it will be started.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
Study: NCT05276362

Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.

Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.

Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.

Intervention type: DEVICE
Intervention: Actiwatch
Description: The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.

Intervention type: DEVICE
Intervention: Actiwatch
Description: The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.

Intervention type: DEVICE
Intervention: Actiwatch
Description: The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
Study: NCT06583044

Intervention type: OTHER
Intervention: Questionnaire
Description: It includes 33 questions measuring awareness and knowledge about bruxism.

Intervention type: OTHER
Intervention: Questionnaire
Description: It includes 33 questions measuring awareness and knowledge about bruxism.
Study: NCT06581354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROVISIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PROVISIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
Study: NCT06397248

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06149494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir
Description: Participants randomized to the experimental cohort will be administered Vapendavir.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo cohort will be administered placebo.
Study: NCT05564455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biometry with Kane formula
Description: Kane formulae for intraocular lens (IOL) power calculation in cataract patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biometry with SRK-T formula
Description: Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
Study: NCT05498558

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT05973916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Description: cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed.
Study: NCT05652985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter-professional Collaboration Training
Description: the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration